Susquehanna Fundamental Investments’s Moleculin Biotech MBRX Stock Holding History

Susquehanna Fundamental Investments’s Portfolio MBRX Stock Details MBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-53	Closed	-$37K	–	1625
2021 Q4	$37K	Sell	53 -20	-27%	-$17.7K	﹤0.01%	1382
2021 Q3	$82K	Sell	73 -10	-12%	-$11.7K	﹤0.01%	1634
2021 Q2	$115K	Sell	83 -1	-1%	-$1.36K	﹤0.01%	1561
2021 Q1	$129K	Buy	+84	New	+$154K	﹤0.01%	1446

Other funds holding MBRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

SPC

Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Susquehanna Fundamental Investments's MBRX Position: Q1 2022 in Review

Susquehanna Fundamental Investments sold out of Moleculin Biotech (MBRX) in Q1 2022, closing a stake of 53 shares — an estimated $37K sold.

Susquehanna Fundamental Investments first reported a position in MBRX in Q1 2021 and held it in 4 quarters. The position peaked at $129K in Q1 2021. 22 funds tracked by Wall St. Rank hold MBRX as of Q1 2022.

Susquehanna Fundamental Investments reported no remaining Moleculin Biotech position as of Q1 2022 after selling out during the quarter.
Susquehanna Fundamental Investments sold 53 Moleculin Biotech shares in Q1 2022, an estimated $37K.
Susquehanna Fundamental Investments first reported a position in Moleculin Biotech in Q1 2021 and held it in 4 quarters.
Susquehanna Fundamental Investments's Moleculin Biotech position peaked at $129K in Q1 2021.
22 funds tracked by Wall St. Rank held Moleculin Biotech as of Q1 2022.

Based on Susquehanna Fundamental Investments's 13F filing for Q1 2022, filed 16 May 2022.